These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29227467)

  • 21. Kinetics of Meningococcal Serogroup C-Specific Functional Antibody Levels Up to 15 Years after a Single Immunization with a Meningococcal Serogroup C Conjugate Vaccine during Adolescence.
    Stoof SP; van Ravenhorst MB; van Rooijen DM; de Voer RM; van der Klis FRM; Boland GJ; Sanders EAM; Berbers GAM; Teunis PF
    Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27881489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.
    Borrow R; Andrews N; Goldblatt D; Miller E
    Infect Immun; 2001 Mar; 69(3):1568-73. PubMed ID: 11179328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
    Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
    Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study.
    Khatami A; Snape MD; Wysocki J; John TM; Westcar S; Mesaros N; Peddiraju K; Boutriau D; Yu LM; Pollard AJ
    Pediatr Infect Dis J; 2012 Oct; 31(10):1069-73. PubMed ID: 22673139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
    Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P
    Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness analyses may underestimate protection of infants after group C meningococcal immunization.
    Vu DM; Kelly D; Heath PT; McCarthy ND; Pollard AJ; Granoff DM
    J Infect Dis; 2006 Jul; 194(2):231-7. PubMed ID: 16779730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction.
    Ishola DA; Borrow R; Findlow H; Findlow J; Trotter C; Ramsay ME
    Clin Vaccine Immunol; 2012 Aug; 19(8):1126-30. PubMed ID: 22647271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
    Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
    Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine.
    Snape MD; Kelly DF; Green B; Moxon ER; Borrow R; Pollard AJ
    Pediatr Infect Dis J; 2005 Feb; 24(2):128-31. PubMed ID: 15702040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil.
    Andrade AL; Minamisava R; Tomich LM; Lemos AP; Gorla MC; de Cunto Brandileone MC; Domingues CMS; de Moraes C; Policena G; Bierrenbach AL;
    Vaccine; 2017 Apr; 35(16):2025-2033. PubMed ID: 28318769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination.
    Block SL; Christensen S; Verma B; Xie F; Keshavan P; Dull PM; Smolenov I
    Vaccine; 2015 Apr; 33(18):2175-82. PubMed ID: 25744224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and duration of protection of primary and booster immunisation against meningococcal serogroup C disease with meningococcal conjugate C and ACWY vaccines: Systematic review.
    Griskaitis M; Thielemann I; Schönfeld V; Falman A; Scholz S; Reinacher U; Haas L; Wichmann O; Harder T
    J Infect; 2024 Sep; 89(3):106228. PubMed ID: 38996818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.
    Basta NE; Borrow R; Berthe A; Dembélé AT; Onwuchekwa U; Townsend K; Boukary RM; Mabey L; Findlow H; Bai X; Sow SO
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S547-53. PubMed ID: 26553687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of conjugate meningococcus C vaccine in pediatric solid organ transplant recipients.
    Zlamy M; Elias J; Vogel U; Frosch M; Jeller V; Cortina G; Jungraithmayr T; Prelog M
    Vaccine; 2011 Aug; 29(37):6163-6. PubMed ID: 21718742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom.
    Auckland C; Gray S; Borrow R; Andrews N; Goldblatt D; Ramsay M; Miller E
    J Infect Dis; 2006 Dec; 194(12):1745-52. PubMed ID: 17109348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistence of serogroup C antibody responses following quadrivalent meningococcal conjugate vaccination in United States military personnel.
    Patel M; Romero-Steiner S; Broderick MP; Thomas CG; Plikaytis BD; Schmidt DS; Johnson SE; Milton AS; Carlone GM; Clark TA; Messonnier NE; Cohn AC; Faix DJ
    Vaccine; 2014 Jun; 32(30):3805-9. PubMed ID: 24837781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
    Borja-Tabora CF; Montalban C; Memish ZA; Boutriau D; Kolhe D; Miller JM; Van der Wielen M
    BMC Infect Dis; 2015 Oct; 15():409. PubMed ID: 26437712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.